Humanized anti-tissue factor antibody, antibody-drug conjugate prepared therefrom and use thereof
US12377160B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Feb 3, 2025 |
| Grant date | Aug 5, 2025 |
| Priority date | — |
| Expiry date | Feb 3, 2045 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided is a humanized anti-tissue factor antibody, an antibody-drug conjugate prepared therefrom and use thereof. The humanized anti-tissue factor antibody has high affinity to tissue factor. Also provided is an antibody-drug conjugate, which is obtained by coupling the humanized anti-tissue factor antibody to a cytotoxic drug. Based on the humanized anti-tissue factor antibody, which has high affinity and short endocytosis time for tumor cells with low-and high-expression of tissue factor, the antibody-drug conjugate can quickly reach the target site of the tumor and exert a cytotoxic effect. The humanized anti-tissue factor antibody can effectively inhibit the growth of tumor cells and the growth of subcutaneous tumors in mice. Therefore, the antibody-drug conjugate of the present disclosure plays an important role in cancer therapy.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.